PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Close on Oct 19, 2026
- Market cap
- $571.61M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $39.00M | $-0.14 | $-0.14 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $37.20M | $-0.03 | $-0.12 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | After market close | $44.60M | $-0.13 | $-0.12 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | – | $-0.13 | $-0.12 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $39.80M | $-0.14 | $-0.13 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $37.20M | $1.44 | $0.15 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 13, 2025 | After market close | $39.20M | $-0.49 | $-0.20 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $40.00M | $-0.22 | $-0.17 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 15, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue | full year 2026 | $155.00M to $165.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Pacific Biosciences Of California filed with the SEC
PacBio Announces Second Quarter 2026 Financial Results
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
PacBio Announces First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Completes Sale of Short-Read Sequencing Assets
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Results of operations · Other events · EX-99.1 to Form 8-K
PacBio Announces Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
PacBio Announces Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
PacBio Announces First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Jim Gibson to join PacBio as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
PacBio Announces Appointment of Chris Smith to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue
Results of operations · Other events · EX-99.1 to Form 8-K
PacBio Announces Third Quarter 2024 Financial
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PacBio Announces Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
PacBio Announces First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
PacBio Announces Preliminary First Quarter 2024
Results of operations · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively
Results of operations · Other events · EX-99.1 to Form 8-K
PacBio Announces Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
PacBio Announces Appointment of David Meline to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PacBio Announces Second Quarter 2023 Financial Results
Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PacBio Enters into Agreement to Acquire Apton Biosystems to Accelerate the Development of a Next Generation, High Throughput, Short-read Sequencer
Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
PacBio Begins Commercialization of the Onso Short-Read Sequencing System
Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.3 to Form 8-K
PacBio Announces a Private Convertible Exchange
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PacBio Announces Record Revenue in First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pacific Biosciences of California, Inc. Announces
Material agreement · Other events · EX-99.1 to Form 8-K
Pacific Biosciences of California, Inc. Announces
Results of operations · Other events · EX-99.1 to Form 8-K
You should consider carefully the risks and
Results of operations · Other events · EX-99.2 to Form 8-K
On behalf of Pacific Biosciences of California, Inc. (the “Company”),
Results of operations · Other events · EX-99.3 to Form 8-K
PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022
Results of operations · Other events · EX-99.1 to Form 8-K
PacBio Announces Third Quarter 2022 Financial Results
Results of operations · Charter or bylaw amendment · EX-99.1 to Form 8-K
PacBio to Report Third Quarter Earnings on November
Results of operations · EX-99.1 to Form 8-K
PacBio Announces Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
PacBio Announces First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K